Last Update 21:24
Monday, 14 October 2019

Rare heart disease drug reduces risk of death by 30 percent in study

The data was presented at the European Society of Cardiology Congress in Munich

Reuters , Monday 27 Aug 2018
Views: 5340
Views: 5340

Pfizer Inc said on Monday that its drug tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent, boosting the prospects of what could be a billion-dollar-a-year drug. 

The study showed that tafamidis reduced all-cause mortality over a 30-month period in patients with transthyretin amyloid cardiomyopathy to 29.5 percent, versus 42.9 percent in patients who received a placebo. It also reduced the rate of cardiovascular-related hospitalization by around 32 percent, Pfizer said.

The data was presented at the European Society of Cardiology Congress in Munich.

“The result is really, phenomenally encouraging and gives fantastic hope for patients with this devastating illness,” said Dr. Brenda Cooperstone, chief development officer of rare disease at Pfizer. “It’s a uniformly fatal disease.” 

Tafamidis is one of 15 potential blockbuster treatments Pfizer is trying to develop. The company’s chief executive officer, Ian Read, has touted Pfizer’s pipeline, arguing that the growth potential from these drugs makes undertaking a large transaction unnecessary. 

But Pfizer believes the disease is underdiagnosed and that there could be 400,000 to 500,000 patients in developed markets around the world. Cooperstone said the current diagnosis rate is only around 0.5 percent to 1 percent.

“Part of that is driven by the fact that today there is no therapy - there’s no reason to actually make the diagnosis,” she said, noting that a real treatment should significantly help improve the diagnosis rate. 

Short link:


Ahram Online welcomes readers' comments on all issues covered by the site, along with any criticisms and/or corrections. Readers are asked to limit their feedback to a maximum of 1000 characters (roughly 200 words). All comments/criticisms will, however, be subject to the following code
  • We will not publish comments which contain rude or abusive language, libelous statements, slander and personal attacks against any person/s.
  • We will not publish comments which contain racist remarks or any kind of racial or religious incitement against any group of people, in Egypt or outside it.
  • We welcome criticism of our reports and articles but we will not publish personal attacks, slander or fabrications directed against our reporters and contributing writers.
  • We reserve the right to correct, when at all possible, obvious errors in spelling and grammar. However, due to time and staffing constraints such corrections will not be made across the board or on a regular basis.

© 2010 Ahram Online.